M&A Deal Summary

Emergent BioSolutions Acquires Bracco - Healthcare Protective Products Division

On August 2, 2013, Emergent BioSolutions acquired medical products company Bracco - Healthcare Protective Products Division from Bracco Diagnostics for 26M USD

Acquisition Highlights
  • This is Emergent BioSolutions’ 2nd transaction in the Medical Products sector.
  • This is Emergent BioSolutions’ 5th largest (disclosed) transaction.
  • This is Emergent BioSolutions’ 6th transaction in the United States.

M&A Deal Summary
Date 2013-08-02
Target Bracco - Healthcare Protective Products Division
Sector Medical Products
Buyer(s) Emergent BioSolutions
Sellers(s) Bracco Diagnostics
Deal Type Divestiture
Deal Value 26M USD

Target

Bracco - Healthcare Protective Products Division

United States
Bracco - Healthcare Protective Products Division includes the RSDL® (decontamination lotion) product that is cleared for marketing by the U.S. Food and Drug Administration (FDA) for removal or neutralization of chemical warfare agents from the skin, diversifies and broadens Emergent’s biodefense franchise into the chemical countermeasure market

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Emergent BioSolutions

Gaithersburg, Maryland, United States
Category Company
Founded 1998
Sector Healthcare Services
Employees1,600
Revenue 1.0B USD (2023)
DESCRIPTION

Emergent BioSolutions is a specialty biopharmaceutical company seeking to protect and enhance life by offering specialized products to healthcare providers and governments to address medical needs and emerging health threats. Emergent BioSolutions was founded in 1998 and is based in Gaithersburg, Maryland.

DEAL STATS #
Overall 6 of 11
Sector (Medical Products) 2 of 2
Type (Divestiture) 4 of 6
Country (United States) 6 of 7
Year (2013) 1 of 1
Size (of disclosed) 5 of 7
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2011-06-06 TenX BioPharma - Monoclonal Antibody Cancer Therapy

United States

TenX BioPharma - Monoclonal Antibody Cancer Therapy includes rights to zanolimumab, an investigational, late-stage monoclonal antibody cancer therapy targeting T-cell lymphomas. Zanolimumab has been evaluated in 130 T-cell lymphoma patients to date. Zanolimumab has received fast track and orphan drug status from the U.S. Food and Drug Administration, and orphan drug status from the European Medicines Agency.

Buy $6M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2014-02-21 Cangene

Winnipeg, Manitoba, Canada

Cangene Corporation is a biopharmaceutical company focused on the development and commercialization of specialty therapeutics, primarily targeting biodefense applications as well as infectious disease, hematology and transplantation.

Buy $222M

Seller(S) 1

SELLER

Bracco Diagnostics

Princeton, New Jersey, United States
Category Company
Founded 1994
Sector Medical Products
DESCRIPTION

Bracco Diagnostics, Inc. is a developer and marketer of imaging agents for use in X-ray/computed tomography, nuclear medicine, and magnetic resonance imaging.

DEAL STATS #
Overall 1 of 2
Sector (Medical Products) 1 of 2
Type (Divestiture) 1 of 2
Country (United States) 1 of 2
Year (2013) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2008-04-02 E-Z-EM

Lake Success, New York, United States

E-Z-EM, Inc. is a manufacturer of contrast agents for gastrointestinal radiology.

Buy $186M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-12-17 Bracco Diagnostics - Gastroenterology Business Unit

Princeton, New Jersey, United States

Bracco Diagnostics, Inc. - Gastroenterology Business Unit (GBU) is a provider of CO2 insufflation systems, devices for biopsy collection and various accessories that improve the workflow and patient experience during an endoscopy procedure.

Sell -
Mergr

Product

Company

Legal